A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.

Lorlatinib, which is already approved and available under the brand name Lobrena in the United States, was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Between the sweat smell, fluorescent lights and omnipresent television screens, April Herring has never connected with going to the gym.

Instead, she runs, bikes, hikes, plays tennis, pickleball and football — anything to get her exercise outside as often as possible.

Extreme weather events have hit parts of Africa relentlessly in the last three years, with tropical storms, floods and drought causing crises of hunger and displacement. They leave another deadly threat behind them: some of the continent's worst outbreaks of cholera.

In southern and East Africa, more than 6,000 people have died and nearly 350,000 cases have been reported since a series of cholera outbreaks began in late 2021.

A University of Hawaii study examining the health effects of last year's deadly wildfires on Maui found that up to 74% of participants may have difficulty breathing and otherwise have poor respiratory health, and almost half showed signs of compromised lung function.

The data, gathered from 679 people in January and February, comes from what researchers hope will be a long-term study of wildfire survivors lasting at least a decade. Researchers released early results from that research on Wednesday. They eventually hope to enroll 2,000 people in their study to generate what they call a snapshot of the estimated 10,000 people affected by the fires.